82
57
Growth Score 82 in past quarter
-5 pts
Heat Score 57 in past quarter
-5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
284676
OSSIANIX is a privately held biotherapeutics company that develops single domain antibodies based on the highly versatile VNAR structure
- Frank S Walsh: Founder and Chief Executive Officer
- J Lynn Rutkowski: Co-founder & Chief Scientific Officer
About the Company
OSSIANIX is a privately held biotherapeutics company that develops single domain antibodies based on the highly versatile VNAR structure from shark. Due to remarkable biological and biophysical properties, the VNAR platform can rapidly deliver unique, exquisitely high-affinity products to multiple target classes and overcomes most disadvantages of
conventional monoclonal antibody therapy. The platform is also ideal for generating bispecific and trispecific products that can be engineered with ease to develop products with differentiated features in clinically meaningful conditions and also allow targeting to both the blood brain barrier and GI tract for CNS and oral applications.
Women Founded

